Table 1.
Paradigms of smart nanomedicine agents for cancer
| Nanomedicine type | Function | Targeted TEM | Imaging method | Therapeutic strategy | Ref. |
|---|---|---|---|---|---|
| DPP-thiophene-4 | pH-responsive nanoprobe | Mild acidity | FL | / | 41 |
| Fe3O4-ZIF-8 | pH/GSH-responsive nanoprobe | Mild acidity and GSH | MRI | / | 42 |
| C–HSA–BOPx–IR825 | pH-responsive nanoprobe | Mild acidity | PAI | / | 43 |
| iNGR-lPNs@DOX | pH-responsive smart nanocarriers | Mild acidity | / | Chemotherapy | 46 |
| DOX@ZIF-8 | pH-responsive smart nanocarriers | Mild acidity | / | Chemotherapy | 47 |
| HA/Ara-IR820@ZIF-8 | pH-responsive smart nanocarriers | Mild acidity | FL | PDT/chemotherapy | 48 |
| PU/CAP | pH-responsive smart nanocarriers | Mild acidity | FL | Chemotherapy | 51 |
| AA-Azo-EG6 | pH-responsive smart nanocarriers | Mild acidity | / | Chemotherapy | 52 |
| PEG-PBLA-Ce6 | pH-responsive nanotheranostic agents | Mild acidity | MRI/FL | PDT | 54 |
| SPB@POM | pH-responsive nanotheranostic agents | Mild acidity | PAI | PTT | 55 |
| CyA-cRGD | GSH-responsive nanomedicine agents | GSH | FL | / | 63 |
| MnO2 nanosheets | GSH-responsive nanomedicine agents | GSH | FL/MRI | / | 64 |
| OEG-2S-SN38 | GSH-responsive smart nanocarriers | GSH | / | Chemotherapy | 68 |
| PEG/Mn-HMSNs | GSH/pH-responsive smart nanocarriers | GSH/mild acidity | MRI | Chemotherapy | 69 |
| MnMoOX-PEG | GSH-responsive nanotheranostic agents | GSH | MRI/PAI | PTT | 75 |
| Au@SiO2 | GSH-responsive nanotheranostic agents | GSH | MRI/PAI | PTT | 76 |
| PEG-PUSeSe-PEG | H2O2-responsive smart nanocarriers | H2O2/GSH | / | Chemotherapy | 86 |
| Ag@MSNs | H2O2-responsive smart nanocarriers | H2O2 | / | Chemotherapy | 87 |
| HAOPs | In situ O2 producer for improving PDT | H2O2 | / | PDT | 92 |
| PCN-224-Pt | In situ O2 producer for improving PDT | H2O2 | / | PDT | 93 |
| FeS2-PEG | H2O2 for chemodynamic therapy | H2O2 and mildly acidic | MRI | CDT | 96 |
| WO3-x@-poly-L-glutamic acid | H2O2 for chemodynamic therapy | H2O2 | PAI | PTT/CDT | 98 |
| MS@MnO2 NPs | H2O2 for chemodynamic therapy | H2O2/GSH | MRI | CDT | 99 |
| BODIPY | H2S-responsive smart nanoprobes | H2S | FL | / | 109 |
| NIR-II@Si | H2S-responsive smart nanoprobes | H2S | FL | / | 110 |
| Si@BODPA | H2S-responsive smart nanoprobes | H2S | PAI | / | 111 |
| Copper–zinc mixed MOF NP-1 | H2S-responsive theranostic agents | H2S | FL | PDT | 116 |
| Cu2O | H2S-responsive theranostic agents | H2S | PAI | PTT | 117 |
Abbreviations: CAP, cellulose acetate phthalate; CDT, chemodynamic therapy; FL, fluorescence imaging; GSH, glutathione; MOF, metal–organic framework; MRI, magnetic resonance imaging; NP, nanoparticle; PAI, photoacoustic imaging; PDT, photodynamic therapy; PEG, polyethylene glycol; PTT, photothermal therapy; PU, polyurethane; DPP, diketopyrrolopyrrole; ZIF, Zeolitic imidazole frameworks; BPOx, benzo[ a ]phenoxazine; HAS, human serum albumin; DOX, doxorubicin; iNRG, CRNGRGPDC; Ara, Cytarabine; HA, hyaluronic acid; PU, polyurethane; AA, amino acid; Azo, azobenezene; EG6, oligoehtyleneglycol; PBLA, poly(β-benzyl-Laspartate); Ce6, chlorin e6; SPB@PON, semiconducting polymer brush and polyoxometalate cluster; CYA, cyanine; RGD, a tumor-targeting unit; OEG, oligo(ethylene glycol); SN38, 7-ethyl-10-hydroxyl-camptothecin; HMSNs, hollow mesoporous silica nanoparticals; MSNs, mesoporous silica nanoparticals; HAOP NP, H2O2-activatable and O2-evolving PDT nanoparticle; PCN-224, porous coordination network-224; MS, mesoporous silica; BODIPY, boron dipyrromethene; NIR‐II, the second near‐infrared window; BODPA, semi-cyanine-BODIPY hybrid dyes.